TBPH vs. NAMS, DVAX, GERN, BLTE, TVTX, IRON, WVE, EVO, PRAX, and AMPH
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include NewAmsterdam Pharma (NAMS), Dynavax Technologies (DVAX), Geron (GERN), Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Wave Life Sciences (WVE), Evotec (EVO), Praxis Precision Medicines (PRAX), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Theravance Biopharma. NewAmsterdam Pharma's average media sentiment score of 0.71 beat Theravance Biopharma's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
Theravance Biopharma has higher revenue and earnings than NewAmsterdam Pharma.
NewAmsterdam Pharma currently has a consensus price target of $41.60, suggesting a potential upside of 124.02%. Theravance Biopharma has a consensus price target of $13.75, suggesting a potential upside of 47.69%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Theravance Biopharma.
NewAmsterdam Pharma has a net margin of 0.00% compared to Theravance Biopharma's net margin of -78.18%. NewAmsterdam Pharma's return on equity of 0.00% beat Theravance Biopharma's return on equity.
NewAmsterdam Pharma has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
Theravance Biopharma received 317 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 62.80% of users gave Theravance Biopharma an outperform vote.
Summary
NewAmsterdam Pharma beats Theravance Biopharma on 11 of the 16 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:TBPH) was last updated on 2/22/2025 by MarketBeat.com Staff
Free TBPH Stock Alerts